AnaptysBio Inc
NASDAQ:ANAB
Intrinsic Value
AnaptysBio, Inc. is a clinical stage biotechnology company. [ Read More ]
The intrinsic value of one ANAB stock under the Base Case scenario is 4.56 USD. Compared to the current market price of 18.87 USD, AnaptysBio Inc is Overvalued by 76%.
Valuation Backtest
AnaptysBio Inc
Run backtest to discover the historical profit from buying and selling ANAB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
AnaptysBio Inc
Current Assets | 406.8m |
Cash & Short-Term Investments | 390.9m |
Receivables | 6.9m |
Other Current Assets | 9.1m |
Non-Current Assets | 45.6m |
Long-Term Investments | 27m |
PP&E | 18.3m |
Other Non-Current Assets | 256k |
Current Liabilities | 37.4m |
Accounts Payable | 4.7m |
Accrued Liabilities | 32.7m |
Non-Current Liabilities | 326.8m |
Other Non-Current Liabilities | 326.8m |
Earnings Waterfall
AnaptysBio Inc
Revenue
|
17.2m
USD
|
Operating Expenses
|
-181.6m
USD
|
Operating Income
|
-164.4m
USD
|
Other Expenses
|
792k
USD
|
Net Income
|
-163.6m
USD
|
Free Cash Flow Analysis
AnaptysBio Inc
ANAB Profitability Score
Profitability Due Diligence
AnaptysBio Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
Score
AnaptysBio Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.
ANAB Solvency Score
Solvency Due Diligence
AnaptysBio Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
AnaptysBio Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ANAB Price Targets Summary
AnaptysBio Inc
According to Wall Street analysts, the average 1-year price target for ANAB is 46.13 USD with a low forecast of 20.2 USD and a high forecast of 84 USD.
Ownership
ANAB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ANAB Price
AnaptysBio Inc
Average Annual Return | 0.71% |
Standard Deviation of Annual Returns | 62.59% |
Max Drawdown | -87% |
Market Capitalization | 501.9m USD |
Shares Outstanding | 26 763 100 |
Percentage of Shares Shorted | 23.57% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
Contact
IPO
Employees
Officers
The intrinsic value of one ANAB stock under the Base Case scenario is 4.56 USD.
Compared to the current market price of 18.87 USD, AnaptysBio Inc is Overvalued by 76%.